Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $538000.0.

  • Theravance Biopharma's Change in Account Payables rose 34454.55% to $538000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $759000.0, marking a year-over-year increase of 29663.21%. This contributed to the annual value of $750000.0 for FY2024, which is 1240000.0% up from last year.
  • As of Q3 2025, Theravance Biopharma's Change in Account Payables stood at $538000.0, which was up 34454.55% from -$733000.0 recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Change in Account Payables registered a high of $5.1 million during Q2 2021, and its lowest value of -$5.7 million during Q4 2021.
  • For the 5-year period, Theravance Biopharma's Change in Account Payables averaged around -$232578.9, with its median value being -$2000.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Theravance Biopharma's Change in Account Payables was 34454.55% (2025), while the steepest drop was 3655000.0% (2025).
  • Over the past 5 years, Theravance Biopharma's Change in Account Payables (Quarter) stood at -$5.7 million in 2021, then soared by 34.46% to -$3.8 million in 2022, then soared by 90.75% to -$348000.0 in 2023, then surged by 326.44% to $788000.0 in 2024, then plummeted by 31.73% to $538000.0 in 2025.
  • Its Change in Account Payables stands at $538000.0 for Q3 2025, versus -$733000.0 for Q2 2025 and $166000.0 for Q1 2025.